Michael Nohaile, Novartis Molecular Diagnostics, Featured at Biomarker Summit, Sept. 5th-7th, Zurich
Michael Nohaile, Global Head of Novartis Molecular Diagnostics, will give a featured presentation on 'The Biomarker is not the end - it's just the beginning' at GTC's 2nd Biomarker Europe Summit (Sept 5th-7th, 2012 in Zurich, Switzerland).
- (1888PressRelease) August 01, 2012 - What do drug discovery and translational scientists need to know to take their qualified biomarkers and turn them into marketable validated companion diagnostics? Sometimes it's not what you know, but who you know. As drug discovery and translational scientists think about using stratification with biomarkers to improve the chances of getting medicines to patients, a number of areas of expertise need to be considered. Getting the right input from the right expert at the right time can make or break your effort to successfully bring a biomarker-based companion diagnostic into clinical practice. Dr Nohaile will give his perspective on what it takes to transform a biomarker into a commercial test.
GTC's 2nd Biomarkers Europe Summit will bring together leading experts across industry and academia to discuss the latest research and developments in the biomarker field, spanning across 3 disease areas, Oncology Biomarkers, Inflammatory Biomarkers, and Neurological Biomarkers.
For more information, please visit www.gtcbio.com
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam